ImmunityBio Bets on the Immune System – EU Approval Drives Biotech Stock
Reading Time: 3 minutes
EU approval as a game changer: Anktiva gets the green light in Europe – the ImmunityBio stock skyrockets (at one point +40%) and now faces the question: reassessment or overvaluation? Fundamentals vs. Hype: Revenue +700%, strong study data – but high cash burn and losses remain the ultimate test for investors. The US biotech company ImmunityBio has moved into the spotlight of investor interest following a landmark decision by the EU Commission and a surge in revenue. The stock has seen a massive rally since the beginning of the year....
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
